| Rituximab (n = 8) | Controls (n = 11) |
---|---|---|
Age (mean/SD) | 62.3 (5.2) | 63.4 (6.4) |
Race (%) | Â | Â |
 White | 7 (87.5) | 10 (90.9) |
 Unknown | 1 (12.5) | 1 (9.1) |
Ethnicity (%) | Â | Â |
 Hispanic | 1 (12.5) | 1 (9.1) |
 Non-hispanic | 6 (75) | 9 (81.8) |
 Unknown | 1 (12.5) | 1 (9.1) |
PSA at diagnosis (mean/SD) | 7.7 (4.7) | 7.5 (4.7) |
Gleason risk group after prostatectomy (n/%) | Â | Â |
 I (GS 3 + 3) | – | 3 (27.3)a |
 II (GS 3 + 4) | 1 (12.5) | – |
 III (GS 4 + 3) | 2 (25) | – |
 IV and V (GS ≥ 8) | 5 (62.5) | 8 (72.7) |
pT stage | Â | Â |
 pT2a-c | 3 (37.5) | 2 (18.2) |
 pT3a-b | 5 (62.5) | 9 (81.8) |